10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

TCRT (Alaunos) Stock Analysis
Buy, Hold or Sell?

Let's analyze Alaunos together

I guess you are interested in Alaunos Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Alaunos’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Alaunos’s Price Targets

I'm going to help you getting a better view of Alaunos Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Alaunos Therapeutics Inc

I send you an email if I find something interesting about Alaunos Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Alaunos (30 sec.)










1.2. What can you expect buying and holding a share of Alaunos? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
20.0%

What is your share worth?

Current worth
$0.65
Expected worth in 1 year
$-1.64
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-2.28
Return On Investment
-45.1%

For what price can you sell your share?

Current Price per Share
$5.06
Expected price per share
$2.45 - $9.8
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Alaunos (5 min.)




Live pricePrice per Share (EOD)
$5.06
Intrinsic Value Per Share
$-86.48 - $191.31
Total Value Per Share
$-85.84 - $191.96

2.2. Growth of Alaunos (5 min.)




Is Alaunos growing?

Current yearPrevious yearGrowGrow %
How rich?$1m$11.6m-$9.2m-385.2%

How much money is Alaunos making?

Current yearPrevious yearGrowGrow %
Making money-$1m-$6.6m$5.6m557.7%
Net Profit Margin-25,106.3%-292,956.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Alaunos (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#731 / 884

Most Revenue
#640 / 884

Most Profit
#244 / 884

Most Efficient
#857 / 884
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Alaunos?

Welcome investor! Alaunos's management wants to use your money to grow the business. In return you get a share of Alaunos.

First you should know what it really means to hold a share of Alaunos. And how you can make/lose money.

Speculation

The Price per Share of Alaunos is $5.06. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alaunos.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alaunos, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.65. Based on the TTM, the Book Value Change Per Share is $-0.57 per quarter. Based on the YOY, the Book Value Change Per Share is $-3.77 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alaunos.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.65-12.9%-0.62-12.3%-4.08-80.7%-3.50-69.1%-6.68-132.0%-10.02-198.1%
Usd Book Value Change Per Share-0.61-12.1%-0.57-11.3%-3.77-74.5%-2.44-48.3%-5.47-108.1%-1.82-36.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%1.1723.1%
Usd Total Gains Per Share-0.61-12.1%-0.57-11.3%-3.77-74.5%-2.44-48.3%-5.47-108.0%-0.66-13.0%
Usd Price Per Share1.47-1.82-0.63-1.17-1.61-3.53-
Price to Earnings Ratio-0.56--0.76--0.12--0.31--0.20--0.40-
Price-to-Total Gains Ratio-2.40--3.32--0.53--1.33--0.88--0.66-
Price to Book Ratio2.28-1.51-0.17-0.58-0.36-3.04-
Price-to-Total Gains Ratio-2.40--3.32--0.53--1.33--0.88--0.66-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.06
Number of shares197
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.57-5.47
Usd Total Gains Per Share-0.57-5.47
Gains per Quarter (197 shares)-112.32-1,076.94
Gains per Year (197 shares)-449.27-4,307.75
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-449-4591-4308-4318
20-899-9081-8617-8626
30-1348-13572-12925-12934
40-1797-18062-17233-17242
50-2246-22553-21542-21550
60-2696-27043-25850-25858
70-3145-31534-30158-30166
80-3594-36025-34467-34474
90-4043-40515-38775-38782
100-4493-45006-43083-43090

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%2.094.00.02.1%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%8.032.00.020.0%24.070.02.025.0%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%8.00.032.020.0%8.00.088.08.3%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%8.032.00.020.0%24.070.02.025.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Alaunos Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.613-0.570-7%-3.768+515%-2.443+299%-5.467+792%-1.823+197%
Book Value Per Share--0.6451.466-56%7.114-91%9.994-94%30.459-98%29.165-98%
Current Ratio--1.0053.610-72%3.890-74%3.204-69%4.393-77%5.834-83%
Debt To Asset Ratio--0.5010.295+70%0.238+111%0.326+54%0.292+71%0.461+9%
Debt To Equity Ratio--1.0040.471+113%0.314+219%0.534+88%0.465+116%1.0050%
Dividend Per Share----0%-0%0.001-100%0.001-100%1.166-100%
Enterprise Value--1667094.4003506914.720-52%5882172.300-72%7532119.776-78%35817173.728-95%43379487.304-96%
Eps---0.654-0.621-5%-4.083+524%-3.499+435%-6.681+921%-10.023+1431%
Ev To Ebitda Ratio---0.388-0.884+128%-0.519+34%-0.612+57%-0.814+110%-0.908+134%
Ev To Sales Ratio--208.387199.135+5%604.290-66%340.377-39%306.023-32%136.943+52%
Free Cash Flow Per Share---0.4713.942-112%-3.479+639%-1.426+203%-4.788+917%-5.411+1049%
Free Cash Flow To Equity Per Share---0.4710.138-440%-5.306+1027%-3.399+622%-5.237+1012%-1.864+296%
Gross Profit Margin--1.0021.001+0%1.000+0%1.058-5%1.184-15%1.092-8%
Intrinsic Value_10Y_max--191.311----------
Intrinsic Value_10Y_min---86.483----------
Intrinsic Value_1Y_max---2.106----------
Intrinsic Value_1Y_min---19.566----------
Intrinsic Value_3Y_max--9.888----------
Intrinsic Value_3Y_min---49.695----------
Intrinsic Value_5Y_max--41.431----------
Intrinsic Value_5Y_min---69.629----------
Market Cap8295971.200+71%2410094.4002989664.720-19%1033922.300+133%1920369.776+26%2637823.728-9%16958062.304-86%
Net Profit Margin---536.500-251.063-53%-2929.563+446%-1134.698+112%-683.675+27%-349.534-35%
Operating Margin---370.500-209.500-43%-954.188+158%-450.784+22%-273.271-26%-144.351-61%
Operating Ratio--548.500257.750+113%1886.250-71%785.741-30%474.296+16%245.163+124%
Pb Ratio7.841+71%2.2781.508+51%0.173+1218%0.577+295%0.361+531%3.044-25%
Pe Ratio-1.933-244%-0.562-0.760+35%-0.119-79%-0.308-45%-0.204-64%-0.402-28%
Price Per Share5.060+71%1.4701.824-19%0.631+133%1.171+26%1.609-9%3.534-58%
Price To Free Cash Flow Ratio-2.687-244%-0.780-0.556-29%-0.107-86%-0.241-69%-0.168-79%-0.483-38%
Price To Total Gains Ratio-8.255-244%-2.398-3.321+38%-0.529-78%-1.327-45%-0.884-63%-0.663-72%
Quick Ratio--0.3021.661-82%2.381-87%1.890-84%3.439-91%4.672-94%
Return On Assets---0.506-0.334-34%-0.494-2%-0.327-35%-0.257-49%-0.228-55%
Return On Equity---1.014-0.522-49%-0.652-36%-0.484-52%-0.373-63%-0.379-63%
Total Gains Per Share---0.613-0.570-7%-3.768+515%-2.442+298%-5.467+792%-0.656+7%
Usd Book Value--1058000.0002404000.000-56%11663500.000-91%16385583.333-94%49937450.000-98%47915550.000-98%
Usd Book Value Change Per Share---0.613-0.570-7%-3.768+515%-2.443+299%-5.467+792%-1.823+197%
Usd Book Value Per Share--0.6451.466-56%7.114-91%9.994-94%30.459-98%29.165-98%
Usd Dividend Per Share----0%-0%0.001-100%0.001-100%1.166-100%
Usd Enterprise Value--1667094.4003506914.720-52%5882172.300-72%7532119.776-78%35817173.728-95%43379487.304-96%
Usd Eps---0.654-0.621-5%-4.083+524%-3.499+435%-6.681+921%-10.023+1431%
Usd Free Cash Flow---772000.0006463000.000-112%-5703500.000+639%-2337750.000+203%-7850750.000+917%-9086450.000+1077%
Usd Free Cash Flow Per Share---0.4713.942-112%-3.479+639%-1.426+203%-4.788+917%-5.411+1049%
Usd Free Cash Flow To Equity Per Share---0.4710.138-440%-5.306+1027%-3.399+622%-5.237+1012%-1.864+296%
Usd Market Cap8295971.200+71%2410094.4002989664.720-19%1033922.300+133%1920369.776+26%2637823.728-9%16958062.304-86%
Usd Price Per Share5.060+71%1.4701.824-19%0.631+133%1.171+26%1.609-9%3.534-58%
Usd Profit---1073000.000-1017750.000-5%-6693500.000+524%-5769250.000+438%-11007650.000+926%-16770900.000+1463%
Usd Revenue--2000.0002500.000-20%1500.000+33%244833.333-99%166800.000-99%519800.000-100%
Usd Total Gains Per Share---0.613-0.570-7%-3.768+515%-2.442+298%-5.467+792%-0.656+7%
 EOD+5 -3MRQTTM+6 -32YOY+23 -153Y+21 -195Y+17 -2310Y+19 -21

3.3 Fundamental Score

Let's check the fundamental score of Alaunos Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.933
Price to Book Ratio (EOD)Between0-17.841
Net Profit Margin (MRQ)Greater than0-536.500
Operating Margin (MRQ)Greater than0-370.500
Quick Ratio (MRQ)Greater than10.302
Current Ratio (MRQ)Greater than11.005
Debt to Asset Ratio (MRQ)Less than10.501
Debt to Equity Ratio (MRQ)Less than11.004
Return on Equity (MRQ)Greater than0.15-1.014
Return on Assets (MRQ)Greater than0.05-0.506
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of Alaunos Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.258
Ma 20Greater thanMa 503.887
Ma 50Greater thanMa 1003.151
Ma 100Greater thanMa 2002.523
OpenGreater thanClose5.022
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Alaunos Therapeutics Inc

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.

Fundamental data was last updated by Penke on 2025-06-17 17:50:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Alaunos earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Alaunos to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -53,650.0%Β means thatΒ $-536.50 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alaunos Therapeutics Inc:

  • The MRQ is -53,650.0%. The company is making a huge loss. -2
  • The TTM is -25,106.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-53,650.0%TTM-25,106.3%-28,543.8%
TTM-25,106.3%YOY-292,956.3%+267,850.0%
TTM-25,106.3%5Y-68,367.5%+43,261.2%
5Y-68,367.5%10Y-34,953.4%-33,414.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-53,650.0%-92.7%-53,557.3%
TTM-25,106.3%-141.4%-24,964.9%
YOY-292,956.3%-186.1%-292,770.2%
3Y-113,469.8%-248.3%-113,221.5%
5Y-68,367.5%-338.6%-68,028.9%
10Y-34,953.4%-488.9%-34,464.5%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Alaunos is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Alaunos to theΒ Biotechnology industry mean.
  • -50.6% Return on Assets means thatΒ Alaunos generatedΒ $-0.51 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alaunos Therapeutics Inc:

  • The MRQ is -50.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -33.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-50.6%TTM-33.4%-17.3%
TTM-33.4%YOY-49.4%+16.1%
TTM-33.4%5Y-25.7%-7.7%
5Y-25.7%10Y-22.8%-2.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-50.6%-11.5%-39.1%
TTM-33.4%-11.6%-21.8%
YOY-49.4%-11.4%-38.0%
3Y-32.7%-11.8%-20.9%
5Y-25.7%-12.1%-13.6%
10Y-22.8%-13.8%-9.0%
4.3.1.3. Return on Equity

Shows how efficient Alaunos is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Alaunos to theΒ Biotechnology industry mean.
  • -101.4% Return on Equity means Alaunos generated $-1.01Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alaunos Therapeutics Inc:

  • The MRQ is -101.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -52.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-101.4%TTM-52.2%-49.2%
TTM-52.2%YOY-65.2%+13.1%
TTM-52.2%5Y-37.3%-14.9%
5Y-37.3%10Y-37.9%+0.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-101.4%-13.6%-87.8%
TTM-52.2%-14.9%-37.3%
YOY-65.2%-14.4%-50.8%
3Y-48.4%-17.0%-31.4%
5Y-37.3%-17.9%-19.4%
10Y-37.9%-20.1%-17.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Alaunos Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Alaunos is operatingΒ .

  • Measures how much profit Alaunos makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Alaunos to theΒ Biotechnology industry mean.
  • An Operating Margin of -37,050.0%Β means the company generated $-370.50 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alaunos Therapeutics Inc:

  • The MRQ is -37,050.0%. The company is operating very inefficient. -2
  • The TTM is -20,950.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-37,050.0%TTM-20,950.0%-16,100.0%
TTM-20,950.0%YOY-95,418.8%+74,468.8%
TTM-20,950.0%5Y-27,327.1%+6,377.1%
5Y-27,327.1%10Y-14,435.1%-12,892.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-37,050.0%-229.2%-36,820.8%
TTM-20,950.0%-250.3%-20,699.7%
YOY-95,418.8%-205.1%-95,213.7%
3Y-45,078.4%-220.2%-44,858.2%
5Y-27,327.1%-342.6%-26,984.5%
10Y-14,435.1%-475.5%-13,959.6%
4.3.2.2. Operating Ratio

Measures how efficient Alaunos is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 548.50 means that the operating costs are $548.50 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Alaunos Therapeutics Inc:

  • The MRQ is 548.500. The company is inefficient in keeping operating costs low. -1
  • The TTM is 257.750. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ548.500TTM257.750+290.750
TTM257.750YOY1,886.250-1,628.500
TTM257.7505Y474.296-216.546
5Y474.29610Y245.163+229.132
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ548.5002.110+546.390
TTM257.7502.704+255.046
YOY1,886.2503.063+1,883.187
3Y785.7413.576+782.165
5Y474.2964.713+469.583
10Y245.1636.512+238.651
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Alaunos Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Alaunos is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 1.00Β means the company has $1.00 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Alaunos Therapeutics Inc:

  • The MRQ is 1.005. The company is just able to pay all its short-term debts.
  • The TTM is 3.610. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ1.005TTM3.610-2.606
TTM3.610YOY3.890-0.280
TTM3.6105Y4.393-0.782
5Y4.39310Y5.834-1.442
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0053.661-2.656
TTM3.6103.786-0.176
YOY3.8904.121-0.231
3Y3.2044.680-1.476
5Y4.3935.765-1.372
10Y5.8346.150-0.316
4.4.3.2. Quick Ratio

Measures if Alaunos is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Alaunos to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.30Β means the company can pay off $0.30 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alaunos Therapeutics Inc:

  • The MRQ is 0.302. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.661. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ0.302TTM1.661-1.359
TTM1.661YOY2.381-0.720
TTM1.6615Y3.439-1.778
5Y3.43910Y4.672-1.233
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3022.826-2.524
TTM1.6613.128-1.467
YOY2.3813.782-1.401
3Y1.8904.304-2.414
5Y3.4395.703-2.264
10Y4.6726.454-1.782
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Alaunos Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of AlaunosΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Alaunos to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.50Β means that Alaunos assets areΒ financed with 50.1% credit (debt) and the remaining percentage (100% - 50.1%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Alaunos Therapeutics Inc:

  • The MRQ is 0.501. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.295. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.501TTM0.295+0.206
TTM0.295YOY0.238+0.057
TTM0.2955Y0.292+0.002
5Y0.29210Y0.461-0.168
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5010.324+0.177
TTM0.2950.347-0.052
YOY0.2380.327-0.089
3Y0.3260.339-0.013
5Y0.2920.349-0.057
10Y0.4610.382+0.079
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Alaunos is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Alaunos to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 100.4% means that company has $1.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alaunos Therapeutics Inc:

  • The MRQ is 1.004. The company is able to pay all its debts with equity. +1
  • The TTM is 0.471. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.004TTM0.471+0.533
TTM0.471YOY0.314+0.156
TTM0.4715Y0.465+0.006
5Y0.46510Y1.005-0.541
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0040.383+0.621
TTM0.4710.436+0.035
YOY0.3140.410-0.096
3Y0.5340.446+0.088
5Y0.4650.460+0.005
10Y1.0050.509+0.496
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Alaunos generates.

  • Above 15 is considered overpriced butΒ always compareΒ Alaunos to theΒ Biotechnology industry mean.
  • A PE ratio of -0.56 means the investor is paying $-0.56Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alaunos Therapeutics Inc:

  • The EOD is -1.933. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.562. Based on the earnings, the company is expensive. -2
  • The TTM is -0.760. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.933MRQ-0.562-1.371
MRQ-0.562TTM-0.760+0.198
TTM-0.760YOY-0.119-0.641
TTM-0.7605Y-0.204-0.556
5Y-0.20410Y-0.402+0.198
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.933-2.197+0.264
MRQ-0.562-2.027+1.465
TTM-0.760-2.527+1.767
YOY-0.119-3.733+3.614
3Y-0.308-3.717+3.409
5Y-0.204-6.036+5.832
10Y-0.402-6.649+6.247
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alaunos Therapeutics Inc:

  • The EOD is -2.687. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.780. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.556. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.687MRQ-0.780-1.906
MRQ-0.780TTM-0.556-0.224
TTM-0.556YOY-0.107-0.449
TTM-0.5565Y-0.168-0.388
5Y-0.16810Y-0.483+0.315
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.687-3.007+0.320
MRQ-0.780-2.704+1.924
TTM-0.556-3.627+3.071
YOY-0.107-4.334+4.227
3Y-0.241-5.070+4.829
5Y-0.168-8.532+8.364
10Y-0.483-9.305+8.822
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Alaunos is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 2.28 means the investor is paying $2.28Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Alaunos Therapeutics Inc:

  • The EOD is 7.841. Based on the equity, the company is overpriced. -1
  • The MRQ is 2.278. Based on the equity, the company is underpriced. +1
  • The TTM is 1.508. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD7.841MRQ2.278+5.563
MRQ2.278TTM1.508+0.770
TTM1.508YOY0.173+1.336
TTM1.5085Y0.361+1.147
5Y0.36110Y3.044-2.683
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD7.8411.921+5.920
MRQ2.2781.843+0.435
TTM1.5082.113-0.605
YOY0.1732.467-2.294
3Y0.5772.541-1.964
5Y0.3613.666-3.305
10Y3.0444.311-1.267
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Alaunos Therapeutics Inc.

4.8.1. Institutions holding Alaunos Therapeutics Inc

Institutions are holding 4.329% of the shares of Alaunos Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31BlackRock Inc1.302402135300
2025-03-31Vanguard Group Inc1.279202097200
2025-03-31Geode Capital Management, LLC0.95210156103942.5894
2024-12-31UBS Group AG0.48078696841665.4669
2025-03-31Tower Research Capital LLC0.10220.0001167652745.866
2025-03-31Morgan Stanley - Brokerage Accounts0.05470897-149-14.2447
2025-03-31Advisor Group Holdings, Inc.0.04390720-140-16.2791
2025-03-31Atlantic Trust Group, LLC0.0183030000
2025-03-31Group One Trading, LP0.0183030000
2024-12-31Wells Fargo & Co0.01690277-96-25.7373
2025-03-31Barclays PLC0.010401711710
2024-12-31Sugarloaf Wealth Management, LLC0.01030.0001169-266-61.1494
2025-03-31Royal Bank of Canada0.00610100-8-7.4074
2025-03-31Steward Partners Investment Advisory, LLC0.00609800
2025-03-31Bank of America Corp0.0054089-49-35.5072
2025-03-31Federation des caisses Desjardins du Quebec0.005208644.878
2025-03-31Bank of Oklahoma National Association0.00406600
2025-03-31Asset Dedication, LLC0.003305400
2025-03-31Newbridge Financial Services Group, Inc.0.001502400
2025-03-31SignatureFD, LLC0.001402300
Total 4.32160.000270854+7229+10.2%

4.9.2. Funds holding Alaunos Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.24860.00012047100
2025-04-30Fidelity Extended Market Index0.56150.00019206-54-0.5832
2025-03-31Extended Equity Market Fund K0.18010295290.3058
2025-04-30Fidelity Total Market Index0.14490237600
2025-04-30Fidelity Series Total Market Index0.1270208200
2025-03-31Northern Trust Extended Eq Market Idx0.08280135700
2025-03-31NT Ext Equity Mkt Idx Fd - L0.08280135700
2025-04-30Fidelity Nasdaq Composite Index0.06810111700
2025-03-31NT Ext Equity Mkt Idx Fd - NL0.06620108600
2025-03-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.05150845-15-1.7442
2025-04-30Spartan Total Market Index Pool G0.0467076500
2025-05-31State St US Extended Mkt Indx NL Cl C0.04540.000174400
2025-04-30Vanguard U.S. Eq Idx Β£ Acc0.0306050100
2025-03-31Extended Equity Market Fund M0.02260370-13-3.3943
2025-03-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.0199032630.9288
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.019703233230
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T40.019703233230
2025-03-31SSgA U.S. Total Market Index Strategy0.019031261.9608
2025-05-31State St US Ttl Mkt Indx NL Cl A0.0099016300
2025-03-31Northern Trust Wilshire 50000.0085014000
Total 2.85550.000346816+582+1.2%

5.3. Insider Transactions

Insiders are holding 11.072% of the shares of Alaunos Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-01Kevin S Sr. BoyleSELL45321
2022-11-29Robert W PostmaBUY500097.5
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Other Current Liabilities  643-101542-174368-192176-776-600



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets2,120
Total Liabilities1,062
Total Stockholder Equity1,058
 As reported
Total Liabilities 1,062
Total Stockholder Equity+ 1,058
Total Assets = 2,120

Assets

Total Assets2,120
Total Current Assets1,067
Long-term Assets1,053
Total Current Assets
Cash And Cash Equivalents 319
Net Receivables 2
Other Current Assets 746
Total Current Assets  (as reported)1,067
Total Current Assets  (calculated)1,067
+/-0
Long-term Assets
Long-term Assets Other 1,053
Long-term Assets  (as reported)1,053
Long-term Assets  (calculated)1,053
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,062
Long-term Liabilities0
Total Stockholder Equity1,058
Total Current Liabilities
Accounts payable 831
Other Current Liabilities -600
Total Current Liabilities  (as reported)1,062
Total Current Liabilities  (calculated)231
+/- 831
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock2
Retained Earnings -921,519
Other Stockholders Equity 922,575
Total Stockholder Equity (as reported)1,058
Total Stockholder Equity (calculated)1,058
+/-0
Other
Capital Stock2
Cash and Short Term Investments 319
Common Stock Shares Outstanding 1,601
Liabilities and Stockholders Equity 2,120
Net Debt -319
Net Invested Capital 1,058
Net Working Capital 5



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-09-302003-06-302003-03-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-09-302000-06-30
> Total Assets 
0
0
0
10
4
3
6
2
1
10
0
0
5
0
0
0
0
1
11,312
9,492
6,308
37,775
35,295
29,512
54,185
48,521
42,801
36,726
29,004
22,458
16,815
12,573
7,873
5,431
8,103
49,736
45,840
74,456
67,450
61,520
130,862
132,821
122,276
108,108
140,873
122,380
105,640
83,404
63,346
45,603
29,478
71,754
63,325
55,348
49,109
45,237
131,648
124,038
173,361
153,724
141,682
128,012
117,122
106,348
94,494
126,813
116,559
105,606
87,461
76,383
66,801
95,051
83,503
73,173
117,949
109,114
198,279
181,679
165,894
146,345
128,472
106,765
113,762
94,865
84,991
73,931
67,344
64,937
48,638
27,927
19,440
8,263
6,037
4,678
3,550
2,755
2,120
2,1202,7553,5504,6786,0378,26319,44027,92748,63864,93767,34473,93184,99194,865113,762106,765128,472146,345165,894181,679198,279109,114117,94973,17383,50395,05166,80176,38387,461105,606116,559126,81394,494106,348117,122128,012141,682153,724173,361124,038131,64845,23749,10955,34863,32571,75429,47845,60363,34683,404105,640122,380140,873108,108122,276132,821130,86261,52067,45074,45645,84049,7368,1035,4317,87312,57316,81522,45829,00436,72642,80148,52154,18529,51235,29537,7756,3089,49211,31210000500101263410000
   > Total Current Assets 
0
0
0
9
3
1
5
1
0
10
0
0
5
0
0
0
0
1
10,950
9,093
5,875
37,349
34,813
28,873
53,275
47,508
41,626
35,528
27,823
21,325
15,769
11,706
7,006
4,696
7,450
49,193
45,356
73,941
66,823
60,816
129,971
131,298
120,417
106,105
138,811
119,442
102,581
80,276
60,561
43,030
27,275
70,297
62,001
54,024
47,814
44,087
130,603
123,080
172,480
152,521
140,389
126,709
115,677
104,884
92,750
125,130
114,888
90,783
72,115
52,993
47,161
84,285
74,093
65,859
115,599
105,492
191,620
173,176
155,071
130,589
112,710
89,407
96,554
78,831
69,772
61,361
55,505
53,799
38,184
18,778
12,869
8,261
6,037
4,678
3,550
2,755
1,067
1,0672,7553,5504,6786,0378,26112,86918,77838,18453,79955,50561,36169,77278,83196,55489,407112,710130,589155,071173,176191,620105,492115,59965,85974,09384,28547,16152,99372,11590,783114,888125,13092,750104,884115,677126,709140,389152,521172,480123,080130,60344,08747,81454,02462,00170,29727,27543,03060,56180,276102,581119,442138,811106,105120,417131,298129,97160,81666,82373,94145,35649,1937,4504,6967,00611,70615,76921,32527,82335,52841,62647,50853,27528,87334,81337,3495,8759,09310,9501000050010015139000
       Cash And Cash Equivalents 
0
0
0
6
1
0
5
0
0
10
0
0
5
0
0
0
0
1
10,741
8,881
1,079
32,577
32,962
26,855
52,701
46,690
40,939
35,029
27,487
21,087
15,192
11,379
6,768
4,543
7,080
48,839
45,044
73,662
66,471
60,392
124,037
130,282
118,933
104,713
128,008
110,391
95,333
73,306
55,655
38,932
23,631
68,204
60,385
53,001
46,122
42,803
129,684
118,550
163,843
140,717
124,846
109,004
94,683
81,053
66,447
97,194
84,406
70,946
51,108
40,404
31,728
61,729
51,487
43,563
88,419
79,741
171,002
153,521
135,471
115,069
100,056
76,746
91,725
76,054
68,255
60,011
37,807
39,058
23,496
18,317
11,944
6,062
4,145
2,463
1,683
1,091
319
3191,0911,6832,4634,1456,06211,94418,31723,49639,05837,80760,01168,25576,05491,72576,746100,056115,069135,471153,521171,00279,74188,41943,56351,48761,72931,72840,40451,10870,94684,40697,19466,44781,05394,683109,004124,846140,717163,843118,550129,68442,80346,12253,00160,38568,20423,63138,93255,65573,30695,333110,391128,008104,713118,933130,282124,03760,39266,47173,66245,04448,8397,0804,5436,76811,37915,19221,08727,48735,02940,93946,69052,70126,85532,96232,5771,0798,88110,7411000050010005016000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,500
4,553
1,536
1,555
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000000000000000000000000000001,5551,5364,5534,50000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,000
0
79
79
0
0
13
58
72
31
449
145
27
32
208
145
62
89
369
446
1,060
15
25
21
67
44
13
19
18
663
1,021
1,864
854
1,460
3,441
3,330
782
4,072
5,428
4,665
5,006
7,626
1,510
1,111
0
1,111
2,911
4
0
4
0
1
1
4
0
5
2
25041104042,9111,11101,1111,5107,6265,0064,6655,4284,0727823,3303,4411,4608541,8641,02166318191344672125151,060446369896214520832271454493172581300797905,0000000000000000000000000000000000010000000
       Other Current Assets 
0
0
0
3
2
1
0
0
0
0
0
0
0
0
0
118
0
0
210
212
296
219
315
463
574
818
687
499
336
238
577
327
238
153
370
354
312
279
352
424
934
1,016
1,405
1,313
10,803
9,051
7,235
6,912
4,834
4,067
3,195
1,948
1,589
991
1,484
1,139
857
4,441
8,268
11,358
14,483
17,690
41,938
47,620
52,472
55,784
60,938
19,818
20,989
11,926
14,412
20,692
43,504
20,836
47,478
22,421
39,672
31,166
28,344
10,855
15,296
10,070
6,638
3,332
3,034
2,700
14,787
799
14,688
457
925
2,198
1,891
2,211
1,867
1,659
746
7461,6591,8672,2111,8912,19892545714,68879914,7872,7003,0343,3326,63810,07015,29610,85528,34431,16639,67222,42147,47820,83643,50420,69214,41211,92620,98919,81860,93855,78452,47247,62041,93817,69014,48311,3588,2684,4418571,1391,4849911,5891,9483,1954,0674,8346,9127,2359,05110,8031,3131,4051,01693442435227931235437015323832757723833649968781857446331521929621221000118000000000123000
   > Long-term Assets 
0
0
0
1
1
1
1
1
0
0
0
0
0
0
0
301
0
0
362
400
433
427
482
639
910
1,013
1,175
1,199
1,181
1,133
1,046
867
867
735
653
543
484
515
627
704
891
1,523
1,859
2,003
2,062
2,938
3,059
3,128
2,785
2,573
2,203
1,457
1,324
1,324
1,295
1,150
1,045
958
881
1,203
1,293
1,303
1,445
1,464
1,744
1,683
1,671
14,823
15,346
23,390
19,640
10,766
9,410
7,314
2,350
3,622
6,659
8,503
10,823
15,756
15,762
17,358
17,208
16,034
15,219
12,570
11,839
11,138
10,454
9,149
6,571
2
2
0
0
0
1,053
1,053000226,5719,14910,45411,13811,83912,57015,21916,03417,20817,35815,76215,75610,8238,5036,6593,6222,3507,3149,41010,76619,64023,39015,34614,8231,6711,6831,7441,4641,4451,3031,2931,2038819581,0451,1501,2951,3241,3241,4572,2032,5732,7853,1283,0592,9382,0622,0031,8591,5238917046275154845436537358678671,0461,1331,1811,1991,1751,01391063948242743340036200301000000011111000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
241
0
0
233
270
302
295
295
451
601
661
719
746
727
675
589
489
489
406
324
255
196
216
230
253
443
549
886
1,141
1,177
1,982
2,108
1,994
1,909
1,713
1,336
801
679
683
654
531
426
321
262
581
667
682
825
843
1,124
1,062
1,047
1,211
1,244
1,332
1,344
1,097
2,556
2,315
2,111
3,382
5,863
7,629
9,947
14,881
15,447
16,977
16,841
15,361
14,551
12,028
11,297
10,596
9,912
8,648
6,571
2
2
0
0
15
0
01500226,5718,6489,91210,59611,29712,02814,55115,36116,84116,97715,44714,8819,9477,6295,8633,3822,1112,3152,5561,0971,3441,3321,2441,2111,0471,0621,1248438256826675812623214265316546836798011,3361,7131,9091,9942,1081,9821,1771,14188654944325323021619625532440648948958967572774671966160145129529530227023300241000000000000000
       Intangible Assets 
0
0
0
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000011111000
       Other Assets 
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
-301
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
875
315
381
367
673
668
542
542
542
0
501
0
0
0
0
0
0
0
00000005010542542542668673367381315875000000000000000000000000000000000000000000000000000000000000000-301000000000100000
> Total Liabilities 
0
0
0
14
12
6
0
2
7
23
15
19
26
14
15
21
18
10
1,748
2,290
2,024
2,677
3,321
2,979
3,398
3,867
5,106
6,357
6,790
6,242
5,761
5,834
4,136
3,753
4,180
21,632
34,454
19,738
25,246
30,967
48,910
48,693
38,164
36,501
43,173
46,744
46,612
34,959
25,453
26,271
25,847
22,371
21,593
17,632
12,632
11,396
11,045
13,597
79,520
66,353
63,869
180,002
59,726
183,646
59,955
56,853
57,289
202,412
61,571
61,190
62,786
9,487
9,287
11,178
11,823
109,114
17,942
18,265
20,976
22,363
22,831
18,484
45,055
36,808
35,869
33,751
35,231
26,382
19,129
6,277
5,540
1,956
1,240
907
826
692
1,062
1,0626928269071,2401,9565,5406,27719,12926,38235,23133,75135,86936,80845,05518,48422,83122,36320,97618,26517,942109,11411,82311,1789,2879,48762,78661,19061,571202,41257,28956,85359,955183,64659,726180,00263,86966,35379,52013,59711,04511,39612,63217,63221,59322,37125,84726,27125,45334,95946,61246,74443,17336,50138,16448,69348,91030,96725,24619,73834,45421,6324,1803,7534,1365,8345,7616,2426,7906,3575,1063,8673,3982,9793,3212,6772,0242,2901,74810182115142619152372061214000
   > Total Current Liabilities 
0
0
0
10
8
0
0
0
0
23
15
19
26
14
15
21
18
10
1,748
2,255
1,988
2,640
3,281
2,938
3,357
3,824
5,070
6,306
6,731
6,181
5,701
5,776
3,956
3,375
3,514
3,095
2,833
2,305
4,106
3,612
6,544
8,691
11,770
13,363
14,330
17,776
21,736
18,864
20,362
20,997
13,362
7,791
7,354
10,788
11,700
10,826
10,492
13,110
29,627
18,123
17,274
16,035
15,744
15,809
17,464
15,988
18,189
20,856
10,062
9,314
60,183
9,483
8,339
10,400
11,176
12,526
16,579
17,112
19,321
18,368
18,961
13,593
28,173
16,041
21,234
26,775
32,869
24,166
17,063
5,052
4,676
1,956
1,240
907
826
692
1,062
1,0626928269071,2401,9564,6765,05217,06324,16632,86926,77521,23416,04128,17313,59318,96118,36819,32117,11216,57912,52611,17610,4008,3399,48360,1839,31410,06220,85618,18915,98817,46415,80915,74416,03517,27418,12329,62713,11010,49210,82611,70010,7887,3547,79113,36220,99720,36218,86421,73617,77614,33013,36311,7708,6916,5443,6124,1062,3052,8333,0953,5143,3753,9565,7765,7016,1816,7316,3065,0703,8243,3572,9383,2812,6401,9882,2551,7481018211514261915230000810000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40,112
146
1,288
1,320
1,354
774
1,656
1,676
1,732
819
1,518
1,530
13,457
9,326
15,483
21,101
23,752
17,881
12,138
678
307
0
0
0
0
0
0
00000030767812,13817,88123,75221,10115,4839,32613,4571,5301,5188191,7321,6761,6567741,3541,3201,28814640,1120000000000000000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,037
7,868
13,993
20,051
22,668
16,765
10,988
0
0
0
0
0
0
0
0
0000000010,98816,76522,66820,05113,9937,86812,0370000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
1
0
0
8
5
5
710
10
10
477
836
545
627
1,144
776
956
1,489
1,638
2,909
2,648
1,900
2,228
2,639
1,621
1,606
1,559
1,789
1,468
1,143
1,088
1,031
1,853
1,784
2,160
1,727
1,984
1,470
4,248
1,509
983
1,165
891
422
578
447
1,953
2,004
779
3,143
4,154
2,008
1,908
2,031
1,814
156
226
81
1,524
4,417
606
588
1,269
707
859
941
926
906
396
1,082
2,619
960
4,190
982
1,463
1,368
605
474
1,984
1,389
1,380
1,479
1,298
616
597
365
458
516
831
8315164583655976161,2981,4791,3801,3891,9844746051,3681,4639824,1909602,6191,0823969069269418597071,2695886064,4171,524812261561,8142,0311,9082,0084,1543,1437792,0041,9534475784228911,1659831,5094,2481,4701,9841,7272,1601,7841,8531,0311,0881,1431,4681,7891,5591,6061,6212,6392,2281,9002,6482,9091,6381,4899567761,1446275458364771010710558001000000000
       Other Current Liabilities 
0
0
0
10
8
0
0
0
0
22
15
19
19
9
10
-689
7
0
1,271
1,419
1,443
2,013
2,137
2,162
2,402
2,335
3,432
3,396
4,083
4,281
3,473
3,137
2,335
1,730
1,909
1,261
1,322
1,139
2,978
2,538
3,862
6,084
8,789
10,573
11,534
15,502
16,682
16,555
18,579
19,032
11,671
6,314
5,976
8,008
8,047
7,045
8,625
9,151
18,540
8,965
8,877
7,615
7,541
8,618
10,849
9,518
10,276
10,050
8,980
8,726
49,513
8,414
6,192
8,139
8,896
10,846
14,527
14,354
14,970
16,573
13,253
11,081
13,253
5,347
5,146
5,200
7,133
4,896
3,545
2,895
3,071
0
643
542
368
176
-600
-60017636854264303,0712,8953,5454,8967,1335,2005,1465,34713,25311,08113,25316,57314,97014,35414,52710,8468,8968,1396,1928,41449,5138,7268,98010,05010,2769,51810,8498,6187,5417,6158,8778,96518,5409,1518,6257,0458,0478,0085,9766,31411,67119,03218,57916,55516,68215,50211,53410,5738,7896,0843,8622,5382,9781,1391,3221,2611,9091,7302,3353,1373,4734,2814,0833,3963,4322,3352,4022,1622,1372,0131,4431,4191,27107-689109191915220000810000
   > Long-term Liabilities 
0
0
0
4
4
6
0
2
7
1
0
0
8
5
5
0
10
10
477
36
36
37
40
41
41
44
36
51
59
60
61
58
180
378
666
18,537
31,621
17,433
21,140
27,355
42,366
40,002
26,394
23,138
28,843
28,968
24,876
16,095
5,091
5,274
12,485
14,580
14,239
6,844
932
570
553
487
49,893
48,230
46,595
163,967
43,982
42,516
42,491
40,865
39,100
37,564
51,509
51,876
2,603
4
948
778
647
1,578
1,363
1,153
1,655
3,995
3,870
4,891
16,882
20,767
14,635
6,976
2,362
2,216
2,066
1,225
864
0
0
0
0
0
0
0000008641,2252,0662,2162,3626,97614,63520,76716,8824,8913,8703,9951,6551,1531,3631,57864777894842,60351,87651,50937,56439,10040,86542,49142,51643,982163,96746,59548,23049,8934875535709326,84414,23914,58012,4855,2745,09116,09524,87628,96828,84323,13826,39440,00242,36627,35521,14017,43331,62118,5376663781805861605951364441414037363647710100558001720644000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,323
4,472
0
0
0
0
0
0
0
0
0
0
0
000000000004,47210,323000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
28
28
28
0
0
0
0
0
0
0
0
0
0000000002828280-100000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
-4
-8
-14
-3
-9
-11
-13
-15
-19
-22
-14
-15
-21
-18
-9
9,564
7,202
4,284
35,098
31,974
26,533
50,787
44,654
37,695
30,370
22,214
16,217
11,053
6,739
3,737
1,678
3,923
28,104
11,386
54,718
42,204
30,553
81,952
84,128
84,112
71,607
97,700
75,636
59,028
48,445
37,893
19,332
3,631
49,383
41,732
37,716
36,477
33,841
120,603
110,441
93,841
87,371
77,813
-51,990
57,396
-77,298
34,539
69,960
59,270
-96,806
25,890
15,193
4,015
85,564
74,216
61,995
106,126
95,010
180,337
163,414
144,918
123,982
105,641
88,281
68,707
58,057
49,122
40,180
32,113
38,555
29,509
21,650
13,900
6,307
4,797
3,771
2,724
2,063
1,058
1,0582,0632,7243,7714,7976,30713,90021,65029,50938,55532,11340,18049,12258,05768,70788,281105,641123,982144,918163,414180,33795,010106,12661,99574,21685,5644,01515,19325,890-96,80659,27069,96034,539-77,29857,396-51,99077,81387,37193,841110,441120,60333,84136,47737,71641,73249,3833,63119,33237,89348,44559,02875,63697,70071,60784,11284,12881,95230,55342,20454,71811,38628,1043,9231,6783,7376,73911,05316,21722,21430,37037,69544,65450,78726,53331,97435,0984,2847,2029,564-9-18-21-15-14-22-19-15-13-11-9-3-14-8-4000
   Common Stock
0
0
0
89
89
0
0
120
120
130
130
130
136
156
156
156
169
184
7
7
7
15
15
15
21
21
21
21
21
21
21
22
22
22
26
42
42
49
49
48
66
68
68
69
80
80
80
83
84
84
84
100
101
101
103
104
128
131
131
132
132
132
132
132
132
142
142
143
142
142
142
161
162
162
181
182
214
214
214
215
215
216
216
216
216
216
216
240
241
241
241
0
16
2
2
2
2
2222160241241241240216216216216216216215215214214214182181162162161142142142143142142132132132132132132131131128104103101101100848484838080806968686648494942422622222221212121212121151515777184169156156156136130130130120120008989000
   Retained Earnings Total Equity00000000-890,675-880,627-871,468-862,572-852,640000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
21
21
21
21
0
0
0
0
0
0
0
15,071
20,504
20,504
20,504
20,504
20,504
20,504
20,504
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-119,045
0
-125,321
0
0
0
-143,992
-143,992
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000-143,992-143,992000-125,3210-119,04500000000000000000000000000000020,50420,50420,50420,50420,50420,50420,50415,071000000021212121000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
901,546
902,536
903,365
918,942
919,943
0
0
0
0
0
0
0
0
00000000919,943918,942903,365902,536901,546000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
30
33
157
176
65
69
78
82
86
74
79
83
5,680
114
118
22,460
22,559
22,860
59,031
59,362
44,668
68,524
68,936
69,300
69,674
70,142
70,645
71,026
91,778
90,548
90,889
96,005
119,206
120,141
154,427
154,118
154,319
244,708
257,606
258,392
259,130
309,682
311,231
312,447
332,086
334,332
334,463
335,474
390,114
392,173
393,733
398,585
406,349
571,318
575,364
576,934
579,939
582,400
702,842
582,225
580,567
578,571
622,052
619,232
615,493
613,302
609,247
604,653
651,732
653,817
656,216
774,324
778,953
882,541
884,214
886,033
887,868
891,081
896,390
899,549
900,693
901,546
902,536
903,365
918,942
919,943
920,857
921,583
0
922,230
922,346
922,426
922,507
922,575
922,575922,507922,426922,346922,2300921,583920,857919,943918,942903,365902,536901,546900,693899,549896,390891,081887,868886,033884,214882,541778,953774,324656,216653,817651,732604,653609,247613,302615,493619,232622,052578,571580,567582,225702,842582,400579,939576,934575,364571,318406,349398,585393,733392,173390,114335,474334,463334,332332,086312,447311,231309,682259,130258,392257,606244,708154,319154,118154,427120,141119,20696,00590,88990,54891,77871,02670,64570,14269,67469,30068,93668,52444,66859,36259,03122,86022,55922,4601181145,68083797486827869651761573330000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue10
Cost of Revenue-0
Gross Profit1010
 
Operating Income (+$)
Gross Profit10
Operating Expense-4,822
Operating Income-4,812-4,812
 
Operating Expense (+$)
Research Development362
Selling General Administrative4,460
Selling And Marketing Expenses0
Operating Expense4,8224,822
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-4,812
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-4,679-4,945
EBIT - interestExpense = -4,679
-4,679
-4,679
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-4,679-4,679
Earnings Before Interest and Taxes (EBITDA)-4,677
 
After tax Income (+$)
Income Before Tax-4,679
Tax Provision-0
Net Income From Continuing Ops-4,679-4,679
Net Income-4,679
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses4,822
Total Other Income/Expenses Net1330
 

Technical Analysis of Alaunos
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Alaunos. The general trend of Alaunos is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Alaunos's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Alaunos Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Alaunos Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 5.35 < 5.622 < 9.8.

The bearish price targets are: 2.7701 > 2.45 > 2.45.

Know someone who trades $TCRT? Share this with them.πŸ‘‡

Alaunos Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Alaunos Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Alaunos Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Alaunos Therapeutics Inc. The current macd is 0.58715063.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Alaunos price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Alaunos. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Alaunos price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Alaunos Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAlaunos Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Alaunos Therapeutics Inc. The current adx is 38.57.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Alaunos shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Alaunos Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Alaunos Therapeutics Inc. The current sar is 4.38.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Alaunos Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Alaunos Therapeutics Inc. The current rsi is 70.26. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Alaunos Therapeutics Inc Daily Relative Strength Index (RSI) ChartAlaunos Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Alaunos Therapeutics Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Alaunos price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Alaunos Therapeutics Inc Daily Stochastic Oscillator ChartAlaunos Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Alaunos Therapeutics Inc. The current cci is 108.55.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Alaunos Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAlaunos Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Alaunos Therapeutics Inc. The current cmo is 40.66.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Alaunos Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAlaunos Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Alaunos Therapeutics Inc. The current willr is -15.61394458.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Alaunos Therapeutics Inc Daily Williams %R ChartAlaunos Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Alaunos Therapeutics Inc. The current atr is 0.53066394.

Alaunos Therapeutics Inc Daily Average True Range (ATR) ChartAlaunos Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Alaunos Therapeutics Inc. The current obv is 24,796,294.

Alaunos Therapeutics Inc Daily On-Balance Volume (OBV) ChartAlaunos Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Alaunos Therapeutics Inc. The current mfi is 80.40.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Alaunos Therapeutics Inc Daily Money Flow Index (MFI) ChartAlaunos Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Alaunos Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-02ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-23MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-25MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside

6.3. Candlestick Patterns

Alaunos Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Alaunos Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.258
Ma 20Greater thanMa 503.887
Ma 50Greater thanMa 1003.151
Ma 100Greater thanMa 2002.523
OpenGreater thanClose5.022
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Alaunos with someone you think should read this too:
  • Are you bullish or bearish on Alaunos? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Alaunos? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Alaunos Therapeutics Inc

I send you an email if I find something interesting about Alaunos Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Alaunos Therapeutics Inc.

Receive notifications about Alaunos Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.